The Home is the New Cancer Center

Handley, Nathan; Bekelman, Justin E.; Binder, Adam

doi:10.6004/jnccn.2020.7626

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, previously published experience demonstrates that systemic cancer therapies can be successfully delivered in patients' homes with safety profiles comparable to infusion center delivery, and it stands to reason that the same could be true for intravesical therapy. 6,7 Others may have concerns over transportation of chemotherapy or immunotherapy agents into their home, including potential risks to others they live with. These data may be obtained through surveys and/or qualitative interviews with NMIBC patients.…”

Section: Knowledge Gaps In Patient-reported Outcomes Of Intravesical ...mentioning

confidence: 99%

In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?

2023

View full text Add to dashboard Cite

Section: Knowledge Gaps In Patient-reported Outcomes Of Intravesical ...mentioning

confidence: 99%

In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?

2023

View full text Add to dashboard Cite

Section: Changes In the Management And Delivery Of Oncology Care In T...mentioning

confidence: 99%

“…Home-based cancer care is safe, feasible, and saves costs 37 . Between 2015 and 2019, the Christie NHS Foundation Trust, Europe’s largest single-site cancer center, provided >11,900 in-home injections or intravenous infusions via a trained nurse, with laptops enabling real-time documentation 37 . The United States Department of Veterans Affairs National Oncology Program manages the largest integrated hematology and oncology services in America, providing care for >43,000 veterans yearly; they have expanded access to cancer treatments through the “Close to Me” program 38 .…”

Section: Changes In the Management And Delivery Of Oncology Care In T...mentioning

confidence: 99%

Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place

Adashek,

Kurzrock

2023

npj Precis. Onc.

View full text Add to dashboard Cite

In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol visits/diagnostic testing. Studies suggest that the travel strain may be greatest among patients living in low‐income areas and/or participating in early-phase studies. In this regard, rare cancers constitute a special unmet need with limited therapeutic options and few trials. Though individually uncommon, rare cancers as a group constitute ~22% of the cancer burden; the portion of cancer burden may even be greater if biomarker-defined rare subsets of either a single cancer type or a tissue-agnostic subgroup are included. Exacerbating the access issue is the fact that, in addition to the paucity of trials, many centers will not activate existing single-arm trials, often due to accrual concerns, which may further disadvantage this patient group and also jeopardize trial completion. Decentralized clinical trials may resolve some of these challenges by allowing patients to participate from close to home. Decentralized clinical trials can take the form of being site-less, with the coordinating body working remotely and care provided by the home oncologist, or by taking the tack of National Cancer Institute/cooperative groups (e.g., NCI-MATCH genomics matching trial or SWOG1609 [NCI] DART immunotherapy rare cancer trial) using a platform design with multiple cohorts and opening at >1000 sites. Decentralized trials now also have supportive FDA guidance. Importantly, home-run trials permit clinical trial access to underserved groups, including those in rural areas and patients financially unable to travel to a central facility.

show abstract

The Importance of Honoring Family Caregiver Burden: Challenges in Mental Health Care Delivery

Applebaum,

Sannes

2024

J Clin Psychol Med Settings

View full text Add to dashboard Cite

The Home is the New Cancer Center

Cited by 4 publications

References 9 publications

In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?

In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?

Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place

The Importance of Honoring Family Caregiver Burden: Challenges in Mental Health Care Delivery

Contact Info

Product

Resources

About